



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	10/665,793
Filing Date	September 19, 2003
First Named Inventor	Edward J. Kaplan
Group Art Unit	
Examiner Name	
Attorney Docket Number	KAP 100 CIP

Sheet 1 of 13

U.S. PATENT DOCUMENTS

Examiner Initials ¹	Cite No. ¹	US Patent Document		Name of Patentee or Applicant of Cited Document	Date of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
		3,993,073		Zaffaroni	11-23-1976	
		4,167,179		Kirsch	09-11-1979	
		4,351,337		Sidman	09-28-1982	
		4,427,005		Tener	01-24-1984	
		4,697,575		Horowitz	10-06-1987	
		4,700,692		Baumgartner	10-20-1987	
		4,706,652		Horowitz	11-17-1987	
		4,754,745		Horowitz	07-05-1988	
		4,763,642		Horowitz	08-16-1988	
		4,815,449		Horowitz	03-28-1989	
		4,820,844		Kagya, et al.	04-11-1989	
		5,030,195		Nardi	07-09-1991	
		5,059,166		Fischell, et al.	10-22-1991	
		5,242,373		Scott, et al.	09-07-1993	
		5,342,283		Good	08-30-1994	

FOREIGN PATENT DOCUMENTS

Examiner Initials ¹	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ³
		Office ²	Number ²	Kind Code ² (if known)				
		PCT	WO 95/03036		Angiogenesis Technologies	02-02-1995		
		PCT	WO 96/14880		PGK Corporation	05-23-1996		
		PCT	WO 97/19706		IBT Technology Partners	06-05-1997		
		PCT	WO 00/32238		Scimed Life Systems, Inc.	06-08-2000		
		PCT	WO 00/41185		Nycomed Amersham PLC	07-13-2000		
		PCT	WO 00/43045		Phlogon, Inc.	07-27-2000		

Examine Signature		Date Considered	
-------------------	--	-----------------	--

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP³ 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

² Unique citation designation number. ³ See attached Kinds of U.S. Patent Documents. ⁴ Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁵ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁷ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement. This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commissioner for Patent, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	10/665,793
Filing Date	September 19, 2003
First Named Inventor	Edward J. Kaplan
Group Art Unit	
Examiner Name	
Attorney Docket Number	KAP 100 CIP

Sheet 2 of 13

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	US Patent Document		Name of Patentee or Applicant of Cited Document	Date of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code* (if known)			
		5,424,288		Order	06-13-1995	
		5,460,592		Langton, et al.	10-24-1995	
		5,486,360		Ballagh, et al.	01-23-1996	
		5,536,726		Order	07-23-1996	
		5,595,979		Snyder	01-21-1997	
		5,620,700		Berggren	04-15-1997	
		5,626,629		Koutrouvills	05-06-1997	
		5,626,662		Brem, et al.	05-06-1997	
		5,650,442		Mitchell, et al.	07-22-1997	
		5,871,437		Alt	02-16-1998	
		5,686,026		Hunter, et al.	03-23-1999	
		6,158,143		Lennox	12-12-2000	
		6,241,982		Nicolini, et al.	06-05-2001	
		6,248,057		Mavity, et al.	06-19-2001	
		6,391,279		Singh et al.	06-21-2002	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ²
		Office*	Number*	Kind Code* (if known)				
		PCT	WO 00/51639		Hatogenetics, Inc.	09-08-2000		
		PCT	WO 00/57923		North American Scientific	10-05-2000		
		PCT	WO 01/36007		Angiotech Pharmaceuticals	05-25-2001		
		PCT	WO 02/30472		Gulford Pharmaceuticals	04-18-2002		

Examine Signature		Date Considered	
-------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3) ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commissioner for Patent, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/665,793
		Filing Date	September 19, 2003
		First Named Inventor	Edward J. Kaplan
		Group Art Unit	
		Examiner Name	
Sheet	4	of	13
		Attorney Docket Number	KAP 100 CIP

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	†
		ALONSO, et al., "Biodegradable microspheres as controlled-release tetanus toxoid delivery systems," <i>Vaccine</i> 12: 299 (1994).	
		*ARCOS, et al., "Biphasic materials for bone grafting and hyperthermia treatment of cancer," <i>J. Biomed. Mater. Res.</i> 65: 71-78 (2003).	
		BEER, et al., "Extended release of adenovirus from polymer microspheres: potential use in gene therapy for brain tumors," <i>Adv. Drug Deliv. Rev.</i> 27: 59 (1997).	
		BENZINA, et al., "Studies on a new radiopaque polymeric biomaterial," <i>Biomaterials</i> 15: 1122 (1994).	
		BREM, et al., "Biodegradable polymers for controlled delivery of chemotherapy with and without radiation therapy in the monkey brain," <i>J. Neurosurg.</i> 80: 283 (1994).	
		BREM, et al., "Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas," <i>J. Neurosurg.</i> 74: 441 (1991).	
		BREM, et al., "Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas," <i>Lancet</i> 345: 1008 (1995).	
		*BOBOFCHAK, et al., "A recombinant polymeric hemoglobin with conformational, functional, and physiological characteristics of an in vivo O ₂ transporter," <i>Am. J. Physiol. Heart Circ. Physiol.</i> 285: H549-H561 (2003).	
		CAMARATA, et al., "Sustained release of nerve growth factor from biodegradable polymer microspheres," <i>Neurosurg.</i> 30: 313 (1992).	
		CARDINALE, et al., "Effect of interstitial and/or systemic delivery of tirapazamine on the radiosensitivity of human glioblastoma multiforme in nude mice," <i>Radiation Oncol. Invest.</i> 6: 63 (1998).	

Examiner's Signature	Date Considered
----------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/665,793
		Filing Date	September 19, 2003
		First Named Inventor	Edward J. Kaplan
		Group Art Unit	
		Examiner Name	
Sheet	5	of	13
		Attorney Docket Number	KAP 100 CIP

OTHER ART - NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	Y ²
		CHATTARAJ, et al., "Biodegradable microparticles of influenza viral vaccine: comparison of the effects of routes of administration on the in vivo immune response in mice," <i>J. Control. Rel.</i> 58: 223 (1999).	
		CHEN, et al., "Carboplatin-loaded PLGA microspheres for intracerebral implantation: in vivo characterization," <i>Drug Deliv.</i> 4: 301 (1997).	
		*CHU, et al., "Biodegradable calcium phosphate nanoparticles as a new vehicle for delivery of a potential ocular hypotensive agent," <i>J. Ocular Pharm. Therapeut.</i> 18: 507-514 (2002).	
		CONFORTI, et al., "Anti-inflammatory activity of polyphosphazene-based naproxen slow-release systems," <i>J. Pharmacol.</i> 48: 488 (1998).	
		DASH & CUDWORTH II, "Therapeutic applications of implantable drug delivery systems," <i>JPM</i> 40: 1 (1998).	
		DOIRON, et al., "Tumor radiosensitization by sustained intratumoral release of bromodeoxyuridine," <i>Cancer Res.</i> 59(15): 3877-3881 (1999).	
		DOMB, et al., "Polyhydrides I: Preparation of high molecular weight polymers," <i>J. Polym. Sci.</i> 25: 3373 (1967).	
		DURING, et al., "Controlled release of dopamine from a polymeric brain implant: in vivo characterization," <i>Ann. Neurol.</i> 25: 351 (1989).	
		EWEND, et al., "Local delivery of chemotherapy and concurrent external beam radiotherapy prolongs survival in metastatic brain tumor models," <i>Research</i> 56: 5217 (1996).	
		FOWLER, et al., "Evaluation of an implant that delivers leuprolide for one year for the palliative treatment of prostate cancer," <i>Urology</i> 55: 639 (2000).	

Examiner's Signature	Date Considered
----------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST, 16 if possible. ⁶ Applicant to place a check mark here if English language translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	10/665,793
				Filing Date	September 19, 2003
				First Named Inventor	Edward J. Kaplan
				Group Art Unit	
				Examiner Name	
Sheet	6	of	13	Attorney Docket Number	KAP 100 CIP

OTHER ART - NON PATENT LITERATURE DOCUMENTS		
Examiner's Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published
		FUNG, et al., "Pharmacokinetics of interstitial delivery of camustine, 4-hydroperoxycyclophosphamide, and paclitaxel from a biodegradable polymer implant in the monkey brain," <i>Cancer Res.</i> 58: 672 (1998).
		*GANZA-GONZALEZ, et al., "Chitosan and chondroitin microspheres for oral-administration controlled release of metoclopramide," <i>Eur. J. Pharm. Biopharm.</i> 48: 149-155 (1999).
		*GEIM, et al., "Microfabricated adhesive mimicking gecko foot-hair," <i>Nature Materials</i> 2: 461-463 (2003).
		GOBIN, et al., "Embolization with radiopaque microbeads of polyacrylonitrile hydrogel: evaluation in swine," <i>Radiology</i> 214: 113 (2000).
		GROSSMAN, et al., "The intracerebral distribution of BCNU delivered by surgically implanted biodegradable polymers," <i>J. Neurosurg.</i> 78: 640 (1992).
		HAFELI, et al., "Effective targeting of magnetic radioactive ⁹⁰ Y-microspheres to tumor cells by an externally applied magnetic field. Preliminary in vitro and in vivo results," <i>Nuclear Med. Biol.</i> 22: 147 (1995).
		HARPER, et al., "Enhanced efficacy of a novel controlled release paclitaxel formulation (PACLIMER Delivery System) for local-regional therapy of lung cancer tumor nodules in mice," <i>Clin. Canc. Res.</i> 5: 4242 (1999).
		*HILGENFELDT, et al., "The acoustics of diagnostic microbubbles: dissipative effects and heat deposition," <i>Ultrasonics</i> 38: 99-104 (2000).
		*HORAK, et al., "New radiopaque polyHEMA-based hydrogel particles," <i>J. Biomed. Mat. Res.</i> 34: 183 (1997).
		HORIUCHI, et al., "Radiotherapy for carcinoma of the tongue with special emphasis on advanced cases," <i>J. Jap. Soc. Cancer Ther.</i> 15(5): 851-857 (1980).

Examiner's Signature	Date Considered
----------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 15 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete If Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	10/665,793	
				Filing Date	September 19, 2003	
				First Named Inventor	Edward J. Kaplan	
				Group Art Unit		
				Examiner Name		
Attorney Docket Number	KAP 100 CIP					
Sheet	7	of	13			

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		*JAISWAL, et al., "Long-term multiple color imaging of live cells using quantum dot bioconjugates," <i>Nature Biotechnol.</i> 21: 47-51 (2003).	
		JUDY, et al., "Effectiveness of controlled release of a cyclophosphamide derivative with polymers against rat gliomas," <i>J. Neurosurg.</i> 82: 481 (1995).	
		*KAKIZAKI, et al., "Lipidhamamicrosphere (LH-M). A new type of totally synthetic oxygen carrier and its oxygen carrying ability," <i>Art. Cells Blood Substit. Immobil.</i> 22: 933-938 (1994).	
		KHARKEVICH, et al., "Employment of magnet-susceptible microparticles for the targeting of drugs," <i>J. Pharm. Pharmacol.</i> 41: 286 (1989).	
		KONG, et al., "Intracranially implanted cisplatin plus systemic carmustine for the treatment of brain tumors in rats," <i>J. Surg. Oncol.</i> 69: 76 (1998).	
		KUSEK, et al., "Prolonged seizure suppression by a single implantable polymeric-TRH microdisk preparation," <i>Brain Res.</i> 609: 189 (1998).	
		KUNOU, et al., "Controlled intraocular delivery of ganciclovir with use of biodegradable scleral implant in rabbits," <i>J. Control. Rel.</i> 37: 143 (1995).	
		KURIAKOSE, et al., "Interleukin-12 delivered by biodegradable microspheres promotes the antitumor activity of human peripheral blood lymphocytes in a human head and neck tumor xenograft/mouse model," <i>Head & Neck</i> p. 57 (2000).	
		LAURENCIN, et al., "Bioadhesive polyanhydrides for antibiotic drug delivery: in vitro osteomyelitis treatment in a rat model system," <i>J. Orthopaedic Res.</i> 11: 256 (1993).	
		*LEBUGLE, et al., "Study of implantable calcium phosphate systems for the slow release of malhotraxata," <i>Biomaterials</i> 23: 3517-3522 (2002).	

Examiner's Signature	Date Considered
----------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449APTO		Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/665,793
		Filing Date	September 19, 2003
		First Named Inventor	Edward J. Kaplan
		Group Art Unit	
		Examiner Name	
Sheet	8	of	13
		Attorney Docket Number	KAP 100 CIP

OTHER ART — NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	Y ²
		LEIBEL & PHILLIPS, <u>Textbook of Radiation Oncology</u> (1998).	
		*LENDLEIN, et al., "Biodegradable, elastic shape-memory polymers for potential biomedical applications," <i>Science</i> 296: 1673-1676 (2002).	
		LESTER, et al., "Assessment of barium impregnated polyethylene spheres (BIPS®) as a measure of solid-phase gastric emptying in normal dogs — comparison to scintigraphy," <i>Vet. Radiol. Ultrasound</i> 40: 465 (1999).	
		LI, et al., "Biodistribution of cyclic carbonate of loxitan: a radiopaque particulate macrophage imaging agent," <i>Acad. Radiol.</i> 3: 500 (1996).	
		*LIANG, et al., "Adhesion force measurements on single gecko setae," <i>Solid-State Sensor and Actuator Workshop</i> 33-38 (2000).	
		MAUER, et al., "Hepatic artery embolisation with a novel radiopaque polymer causes extended liver necrosis in pigs due to occlusion of the concomitant portal vein," <i>J. Hepatology</i> 32: 261 (2000).	
		MENEI, et al., "Local and sustained delivery of 5-fluorouracil from biodegradable microspheres for the radiosensitization of glioblastoma," <i>Cancer</i> 86: 325 (1999).	
		*MERRICK, et al., "Seed flux in the prostate/paraprostatic region following brachytherapy," <i>Int. J. Radiation Oncol. Biol. Phys.</i> 46: 215-220 (2000).	
		*MINAMIMURA, et al., "Tumor regression by inductive hyperthermia combined with hepatic embolization using dextran magnetite-incorporated microspheres in rats," <i>Int. J. Oncol.</i> 16: 1153-1158 (2000).	
		*MITSUMORI, et al., "Development of intra-arterial hyperthermia using a dextran-magnetite complex," <i>Int. J. Hyperthermia</i> 10: 785-793 (1994).	

Examiner's Signature	Date Considered
----------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/665,793
		Filing Date	September 19, 2003
		First Named Inventor	Edward J. Kaplan
		Group Art Unit	
		Examiner Name	
Sheet	9	of	13
		Attorney Docket Number	KAP 100 CIP

OTHER ART — NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country when published	Y ²
		MIYAMOTO, et al., "Biodegradable scleral implant for intravitreal controlled release of fluconazole," <i>Curr. Eye Res.</i> 18: 930 (1997).	
		MORITERA, et al., "Biodegradable microspheres containing adriamycin in the treatment of proliferative vitreoretinopathy," <i>Invest. Ophthalmol. Vis. Sci.</i> 33: 3125 (1992).	
		*MOROZ, et al., "Arterial embolization hyperthermia in porcine renal tissue," <i>J. Surg. Res.</i> 105: 209-214 (2002).	
		PARK, et al., "Biodegradable polyanhydride devices of celastrol sodium, bupivacaine, and texol for local drug delivery: preparation and kinetics and mechanism of in vitro release," <i>J. Control. Rel.</i> 52: 179 (1998).	
		PEREZ & BRADY, <i>Principles and Practice of Radiation Oncology</i> , 3 rd ed, p. 54 (1998).	
		*PERKA, et al., "The use of fibrin beads for tissue engineering and subsequenceal transplantation," <i>Tiss. Eng.</i> 7: 359-361 (2001).	
		PHILIPPE, et al., "Local and sustained delivery of 5-fluorouracil from biodegradable microspheres for the radiosensitization of glioblastoma," <i>Cancer</i> 88: 325 (1999).	
		*POGGI, et al., "Marker and seed migration in prostate localization," <i>Int. J. Radiation Oncol. Biol. Phys.</i> 56: 1248-1251 (2003).	
		PRESTIDGE, et al., "Post-treatment biopsy results following permanent transrectal ultrasound-guided interstitial brachytherapy in early stage prostate cancer," <i>Int. J. Radiation Oncol. Biol. Phys.</i> 32(Suppl 1): 144 (1995).	
		QIAN, et al., "Fabrication and characterization of controlled release poly(D,L-lactide-co-glycolide) millirods," <i>J. Biomed. Mater. Res.</i> 55: 512 (2001).	

Examiner's Signature	Date Considered
----------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible. ⁶ Applicant to place a check mark here if English language translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/666,793
		Filing Date	September 19, 2003
		First Named Inventor	Edward J. Kaplan
		Group Art Unit	
		Examiner Name	
Sheet	10	of	13
		Attorney Docket Number	KAP 100 CIP

OTHER ART - NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	Y ²
		RAMIREZ, et al., "Biodegradable poly(DL-lactic-co-glycolic acid) microspheres containing tetracaine hydrochloride. In-vitro release profile," <i>J. Microencapsulation</i> 16: 105 (1999).	
		REINHARD, et al., "Polymeric controlled release of dexamethasone in normal rat brain," <i>J. Control. Rel.</i> 16: 331 (1991).	
		RINGKJOB, "Treatment of intracranial gliomas and metastatic carcinomas by local application of cytostatic agents," <i>Acta Neurol. Scandinau.</i> 44: 318 (1968).	
		*ROBERTO, et al., "Structure and dosimetric analysis of biodegradable glasses for prostate cancer treatment," <i>Art. Organs</i> 27: 432-433 (2003).	
		SANCHEZ, et al., "In vivo study of the tissue distribution and immunosuppressive response of cyclosporin A-loaded polyester micro- and nanospheres," <i>Drug Deliv.</i> 2: 21 (1995).	
		*SCHEIBEL, et al., "Conducting nanowires built by controlled self-assembly of amyloid fibers and selective metal deposition," <i>Proc. Natl. Acad. Sci.</i> 100: 4527-4532 (2003).	
		SEE, et al., "Brachytherapy and continuous infusion 5-fluorouracil for the treatment of local advanced, lymph node negative, prostate cancer," <i>Cancer</i> 77(5): 924-927 (1996).	
		*SENDEROFF, et al., "Fibrin based drug delivery systems," <i>J. Parenter. Sci. Technol.</i> 45: 2-6 (1991).	
		*SIVAKUMAR, et al., "Preparation, characterization and in vitro release of gentamicin from coraline hydroxyapatite-gelatin composite microspheres," <i>Biomaterials</i> 23: 3175-3181 (2002).	
		STRAW, et al., "Effects of cis-diaminedichloroplatinum II released from D,L-poly(lactic acid) implanted adjacent to cortical allografts in dogs," <i>J. Orthopaedic Res.</i> 12: 871 (1994).	
Examiner's Signature	Date Considered		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/665,793
		Filing Date	September 19, 2003
		First Named Inventor	Edward J. Kaplan
		Group Art Unit	
		Examiner Name	
Attorney Docket Number	KAP 100 CIP		
Sheet	11	of	13

OTHER ART - NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	†
		"SUNDBACK, et al., "Manufacture of porous polymer nerve conduits by a novel low-pressure injection molding process," <i>Biomaterials</i> 24: 819-830 (2003).	
		TAMARGO, et al., "Growth inhibition of the 9L glioma using polymers to release heparin and cortisone acetate," <i>J. Neurooncol.</i> 9: 131 (1990).	
		TAMARGO, et al., "Interstitial chemotherapy of the 9L gliosarcoma: controlled release polymers for drug delivery in the brain," <i>Cancer Res.</i> 53: 329 (1993).	
		TAMARGO, et al., "Interstitial delivery of dexamethasone in the brain for the reduction of peritumoral edema," <i>J. Neurosurg.</i> 74: 958 (1991).	
		"TAPEN, et al., "Reduction of radioactive seed embolization to the lung following prostate brachytherapy," <i>Biomed. 24: 819-830 (2003).</i>	
		THANOO & JAYAKRISHNAN, "Radiopaque hydrogel microspheres," <i>J. Microencapsulation</i> 6: 233 (1989).	
		THANOO, et al., "Tantalum-loaded polyurethane microspheres for particulate embolization: preparation and properties," <i>Biomaterials</i> 12: 525 (1991).	
		VALTONEN, et al., "Interstitial chemotherapy with carmustine-loaded polymers for high-grade gliomas: a randomized double-blind study," <i>Neurosurg.</i> 41: 44 (1997).	
		"VIROONCHATAPAN, et al., "Preparation and characterization of dextran magnetite-incorporated thermosensitive liposomes: an on-line flow system for quantifying magnetic responsiveness," <i>Pharm. Res.</i> 12: 1176-1183 (1995).	
		WALTER, et al., "Interstitial taxol delivered from a biodegradable polymer implant against experimental malignant glioma," <i>Cancer Res.</i> 54: 2207 (1994).	

Examiner's Signature		Date Considered	
----------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

† Unique citation designation number. ‡ See attached Kinds of U.S. Patent Documents. § Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3). ¶ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ** Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. †† If possible. ‡‡ Applicant to place a check mark here if English language translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/665,793
		Filing Date	September 19, 2003
		First Named Inventor	Edward J. Kaplan
		Group Art Unit	
		Examiner Name	
Sheet	12	of	13
		Attorney Docket Number	KAP 100 CIP

OTHER ART -- NON PATENT LITERATURE DOCUMENTS		
Examiner's Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published
		"WANG, et al., "A tough biodegradable elastomer," <i>Nature Biotechnol.</i> 20: 602-606 (2002).
		WANG, et al., "Intratumoral injection of rhenium-188 microspheres into an animal model of hepatoma," <i>J. Nucl. Med.</i> 39: 1752 (1998).
		WEI, et al., "Carboplatin-loaded PLGA microspheres for intracerebral implantation: in vivo characterization," <i>Drug Delivery</i> 4: 301 (1997).
		WEINGART, et al., "Local delivery of dexamethasone in the brain for the reduction of peritumoral edema," <i>Int. J. Cancer</i> 62: 1 (1995).
		WILLIAMS, et al., "Synthetic, implantable polymers for local delivery of IUDR to experimental human malignant glioma," <i>Int. J. Radiation Oncol. Biol. Phys.</i> 42: 631 (1998).
		WUNDERLICH, et al., "Preparation and biodistribution of rhenium-188 labeled albumin microspheres B 20: a promising new agent for radiotherapy," <i>Appl. Radiation Isotopes</i> 52: 63 (2000).
		YANG, et al., "Diagnostic and therapeutic potential of poly(D,L-glutamate)," <i>J. Pharm. Sci.</i> 83: 328 (1994).
		YAPP, et al., "Cisplatin delivery by biodegradable polymer implant is superior to systemic delivery by osmotic pump or i.p. injection in tumor-bearing mice," <i>Anti-Cancer Drugs</i> 9: 791 (1998).
		YAPP, et al., "The potentiation of the effect of radiation treatment by intratumoral delivery of cisplatin," <i>Int. J. Radiation Oncol. Biol. Phys.</i> 42: 413 (1998).
		YAPP, et al., "Tumor treatment by sustained intratumoral release of cisplatin: effects of drug alone and combined with radiation," <i>Int. J. Radiation Oncol. Biol. Phys.</i> 39: 497 (1998).

Examiner's Signature	Date Considered
----------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language translation is attached.

Burden Hour Statement. This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete If Known

Application Number	10/665,793
--------------------	------------

Filing Date	September 19, 2003
-------------	--------------------

First Named Inventor	Edward J. Kaplan
----------------------	------------------

Group Art Unit	1518
----------------	------

Examiner Name _____

Attorney Docket Number	KAP 100 CIP
------------------------	-------------

Sheet	1	of
-------	---	----

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

Examiner's Signature	Date Considered
----------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See Attached Kinds of U.S. Patent Documents, ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indicator of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.

